Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, Esposito G, De Chiara A, Morelli E, Capobianco G, Becchimanzi C, Volzone F, Saggese M, Marcacci G, De Filippi R, Vitolo U, Pinto A. Corazzelli G, et al. Among authors: arcamone m. Br J Haematol. 2012 Jan;156(2):234-44. doi: 10.1111/j.1365-2141.2011.08947.x. Epub 2011 Nov 21. Br J Haematol. 2012. PMID: 22098541 Free article. Clinical Trial.
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
Corazzelli G, Capobianco G, Arcamone M, Ballerini PF, Iannitto E, Russo F, Frigeri F, Becchimanzi C, Marcacci G, De Chiara A, Pinto A. Corazzelli G, et al. Among authors: arcamone m. Cancer Chemother Pharmacol. 2009 Oct;64(5):907-16. doi: 10.1007/s00280-009-0941-9. Epub 2009 Feb 15. Cancer Chemother Pharmacol. 2009. PMID: 19219604
Elevation of clonal serum free light chains in patients with HIV-negative primary effusion lymphoma (PEL) and PEL-like lymphoma.
De Filippi R, Iaccarino G, Frigeri F, Di Francia R, Crisci S, Capobianco G, Arcamone M, Becchimanzi C, Amoroso B, De Chiara A, Corazzelli G, Pinto A. De Filippi R, et al. Among authors: arcamone m. Br J Haematol. 2009 Nov;147(3):405-8. doi: 10.1111/j.1365-2141.2009.07846.x. Epub 2009 Aug 13. Br J Haematol. 2009. PMID: 19681885 Free article. No abstract available.
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy.
Corazzelli G, Frigeri F, Arcamone M, Lucania A, Rosariavilla M, Morelli E, Amore A, Capobianco G, Caronna A, Becchimanzi C, Volzone F, Marcacci G, Russo F, De Filippi R, Mastrullo L, Pinto A. Corazzelli G, et al. Among authors: arcamone m. Br J Haematol. 2011 Sep;154(5):579-89. doi: 10.1111/j.1365-2141.2011.08786.x. Epub 2011 Jun 28. Br J Haematol. 2011. PMID: 21707585 Free PMC article. Clinical Trial.
Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas.
Corazzelli G, Frigeri F, Arcamone M, Aloj L, Capobianco G, Becchimanzi C, Morelli E, Volzone F, Marcacci G, Russo F, De Filippi R, Lastoria S, Pinto A. Corazzelli G, et al. Among authors: arcamone m. Eur J Haematol. 2011 Dec;87(6):547-53. doi: 10.1111/j.1600-0609.2011.01683.x. Epub 2011 Jul 31. Eur J Haematol. 2011. PMID: 21752099 Free PMC article.
Feasibility of bremsstrahlung dosimetry for direct dose estimation in patients undergoing treatment with 90Y-ibritumomab tiuxetan.
Arrichiello C, Aloj L, Mormile M, D'Ambrosio L, Frigeri F, Caracò C, Arcamone M, De Martinis F, Pinto A, Lastoria S. Arrichiello C, et al. Among authors: arcamone m. Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):956-66. doi: 10.1007/s00259-011-2040-5. Epub 2012 Jan 12. Eur J Nucl Med Mol Imaging. 2012. PMID: 22237846 Clinical Trial.
19 results